Dermata Therapeutics Inc (DRMA)

$2.26 +0.06 (2.73%)
Market Cap 2.24M
Revenue (ttm) 0.00
Net Income (ttm) -12.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 103,436
Avg Vol 1,082,744
Day's Range N/A - N/A
Shares Out 1.03M
Stochastic %K 55%
Beta 0.54
Analysts Strong Sell
Price Target $10.00

Company Profile

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 800 2543
Address:
3525 Del Mar Heights Rd., Suite 332, San Diego, United States
HolEKa1010
HolEKa1010 Jan. 5 at 6:45 PM
$DRMA $4 price target for me 🥰
0 · Reply
CDAinvestor
CDAinvestor Jan. 5 at 6:36 PM
$RGC $DRMA
0 · Reply
16Zx10r
16Zx10r Jan. 5 at 6:28 PM
$SIDU $ORBS $DRMA
0 · Reply
Goldwave9
Goldwave9 Jan. 5 at 3:04 PM
$DRMA appears to coiling... waiting to see the effect on the warrants today and tomorrow. High risk. Higher rewards.
0 · Reply
DonZulu
DonZulu Jan. 5 at 2:49 PM
$DRMA bottoms in loading up low 2s
0 · Reply
Kaz007
Kaz007 Jan. 5 at 7:40 AM
$DRMA break 2.7.
0 · Reply
Rampageusa
Rampageusa Jan. 4 at 7:39 PM
$DRMA $SOPA
0 · Reply
CDAinvestor
CDAinvestor Jan. 3 at 9:51 PM
$DRMA great sign. Passive investors taking a greater than 5% ownership with no control. Huge vote of confidence! https://archive.fast-edgar.com/20260102/AR2TK22CL222U9A2222G2ZY2ANTTZ2224282/
0 · Reply
MrTicker
MrTicker Jan. 2 at 11:10 PM
$DRMA Form SCHEDULE 13G Dermata Therapeutics, Filed by: INTRACOASTAL CAPITAL, LLC 10K WIZARD 3:54 PM ET 1/2/2026 http://archive.fast-edgar.com/20260102/AR2TK22CL222U9A2222G2ZY2ANTTZ2224282 Filed on: January 2, 2026
0 · Reply
Rampageusa
Rampageusa Jan. 2 at 9:42 PM
$DRMA ,$NCL could go double from here next week or before ..
0 · Reply
Latest News on DRMA
Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 29, 2025, 4:05 PM EST - 8 days ago

Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 24, 2025, 8:00 AM EST - 13 days ago

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity

Dec 4, 2025, 8:00 AM EST - 4 weeks ago

A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 4:05 PM EST - 7 weeks ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

Oct 2, 2025, 8:00 AM EDT - 3 months ago

Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

Sep 17, 2025, 1:00 AM EDT - 3 months ago

Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025

Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

Sep 16, 2025, 8:35 AM EDT - 4 months ago

Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

Sep 10, 2025, 8:00 AM EDT - 4 months ago

Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 5:00 PM EDT - 5 months ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

Jul 8, 2025, 8:00 AM EDT - 6 months ago

Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 14, 2025, 9:00 AM EDT - 8 months ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

Apr 15, 2025, 8:30 AM EDT - 9 months ago

Dermata's XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Mar 27, 2025, 8:15 PM EDT - 10 months ago

Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne

Mar 27, 2025, 10:21 AM EDT - 10 months ago

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne

Dermata Therapeutics Shares Surge on Positive Acne Treatment Study

Mar 27, 2025, 9:57 AM EDT - 10 months ago

Dermata Therapeutics Shares Surge on Positive Acne Treatment Study

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Mar 27, 2025, 8:00 AM EDT - 10 months ago

BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Mar 17, 2025, 4:16 PM EDT - 10 months ago

Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Mar 4, 2025, 8:03 AM EST - 11 months ago

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Feb 25, 2025, 7:58 AM EST - 11 months ago

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

Dermata to Present on BioPub on January 31, 2025

Jan 29, 2025, 4:05 PM EST - 1 year ago

Dermata to Present on BioPub on January 31, 2025

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment

Jan 28, 2025, 4:05 PM EST - 1 year ago

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 23, 2025, 4:15 PM EST - 1 year ago

Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jan 22, 2025, 8:00 AM EST - 1 year ago

Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Jan 21, 2025, 8:00 AM EST - 1 year ago

Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dec 16, 2024, 9:00 AM EST - 1 year ago

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dec 10, 2024, 9:00 AM EST - 1 year ago

Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dec 3, 2024, 9:00 AM EST - 1 year ago

Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 4:15 PM EST - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Nov 11, 2024, 8:35 AM EST - 1 year ago

Dermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Oct 8, 2024, 4:15 PM EDT - 1 year ago

Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 17, 2024, 5:15 PM EDT - 1 year ago

Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 16, 2024, 9:00 PM EDT - 1 year ago

Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Jul 17, 2024, 9:00 AM EDT - 1 year ago

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

May 17, 2024, 8:30 AM EDT - 1 year ago

Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 15, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Dermata to Present at the Emerging Growth Conference on April 3, 2024

Mar 27, 2024, 4:05 PM EDT - 1 year ago

Dermata to Present at the Emerging Growth Conference on April 3, 2024

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

Mar 21, 2024, 4:05 PM EDT - 1 year ago

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results

Dermata to Present at the Emerging Growth Conference on February 7, 2024

Feb 1, 2024, 9:00 AM EST - 2 years ago

Dermata to Present at the Emerging Growth Conference on February 7, 2024

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis

Jan 4, 2024, 4:05 PM EST - 2 years ago

Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dec 20, 2023, 4:05 PM EST - 2 years ago

Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Nov 16, 2023, 1:30 PM EST - 2 years ago

Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

Nov 16, 2023, 8:00 AM EST - 2 years ago

Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 4:05 PM EST - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial

Oct 26, 2023, 9:00 AM EDT - 2 years ago

Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial

Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 31, 2023, 9:00 AM EDT - 2 years ago

Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Aug 10, 2023, 4:15 PM EDT - 2 years ago

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne

Jun 27, 2023, 9:00 AM EDT - 2 years ago

Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne

Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

Jun 13, 2023, 4:15 PM EDT - 2 years ago

Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

HolEKa1010
HolEKa1010 Jan. 5 at 6:45 PM
$DRMA $4 price target for me 🥰
0 · Reply
CDAinvestor
CDAinvestor Jan. 5 at 6:36 PM
$RGC $DRMA
0 · Reply
16Zx10r
16Zx10r Jan. 5 at 6:28 PM
$SIDU $ORBS $DRMA
0 · Reply
Goldwave9
Goldwave9 Jan. 5 at 3:04 PM
$DRMA appears to coiling... waiting to see the effect on the warrants today and tomorrow. High risk. Higher rewards.
0 · Reply
DonZulu
DonZulu Jan. 5 at 2:49 PM
$DRMA bottoms in loading up low 2s
0 · Reply
Kaz007
Kaz007 Jan. 5 at 7:40 AM
$DRMA break 2.7.
0 · Reply
Rampageusa
Rampageusa Jan. 4 at 7:39 PM
$DRMA $SOPA
0 · Reply
CDAinvestor
CDAinvestor Jan. 3 at 9:51 PM
$DRMA great sign. Passive investors taking a greater than 5% ownership with no control. Huge vote of confidence! https://archive.fast-edgar.com/20260102/AR2TK22CL222U9A2222G2ZY2ANTTZ2224282/
0 · Reply
MrTicker
MrTicker Jan. 2 at 11:10 PM
$DRMA Form SCHEDULE 13G Dermata Therapeutics, Filed by: INTRACOASTAL CAPITAL, LLC 10K WIZARD 3:54 PM ET 1/2/2026 http://archive.fast-edgar.com/20260102/AR2TK22CL222U9A2222G2ZY2ANTTZ2224282 Filed on: January 2, 2026
0 · Reply
Rampageusa
Rampageusa Jan. 2 at 9:42 PM
$DRMA ,$NCL could go double from here next week or before ..
0 · Reply
Dwaynetrader
Dwaynetrader Jan. 2 at 5:15 PM
$DRMA Pump to dumpster
2 · Reply
Goldwave9
Goldwave9 Jan. 2 at 4:41 PM
$DRMA if you went to the bathroom, you missed the 2.68 high. But fear not, it will be back again... sooner than later...
1 · Reply
www_larval_com
www_larval_com Jan. 2 at 4:37 PM
Dur-dur look @ $DRMA just dropped -8% lower to -5% (~371Kv) a moment ago, follow for more volatility.
0 · Reply
PETErva
PETErva Jan. 2 at 3:45 PM
$DRMA
1 · Reply
Stonksgocraycraycray
Stonksgocraycraycray Jan. 2 at 3:36 PM
$AUPH Hop over to $DRMA bout to rocket $MU $USAR
0 · Reply
only1mc
only1mc Jan. 2 at 3:35 PM
$DRMA starting to fly under the radar $SOPA pushed down found is ledge another slow climb up
0 · Reply
bowlerhatsftw
bowlerhatsftw Jan. 2 at 3:34 PM
$DRMA low key expansion
0 · Reply
only1mc
only1mc Jan. 2 at 3:34 PM
$DRMA starting to get jumpy. let's go
0 · Reply
only1mc
only1mc Jan. 2 at 3:20 PM
$DRMA keep going
0 · Reply
Rizer20MM
Rizer20MM Dec. 31 at 11:39 PM
$DRMA The squeeze potential is very high on this one, with a high target range of ~ $3.50-$4, if price action and volume support the move.
0 · Reply
Rizer20MM
Rizer20MM Dec. 31 at 8:34 PM
$DRMA $2.42 must become a level of support in order to continue up.
0 · Reply